Sort   by:  
 Page size 
Proteasome inhibition constitutes a cornerstone of multiple myeloma (MM) treatment, with bortezomib, carfilzomib and ixazomib approved for clinical use. We observed a consistent and highly significant increase in the reticulocyte count during treatment with carfilzomib-based regimens in patients wi...
ORGANISM(S): Homo sapiens (Human) 
2020-02-20 | PXD014353 | Pride
Sort   by:  
 Page size